Note: Descriptions are shown in the official language in which they were submitted.
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
METHOD FOR REMOVING ENDOTOXIN FROM PROTEINS
[001] This application claims the benefit of priority of earlier-filed United
States
provisional application number 60/948,839, filed July 10, 2007.
Field of the Invention
[002] The invention relates to methods for removing endotoxin from proteins.
More
specifically, the invention relates to methods for removing endotoxin from
proteins which
bind endotoxin and to products produced by that process.
Background of the Invention
[003] The term "endotoxin" is most commonly used to refer to a
lipopolysaccharide
complex associated with the outer membrane of Gram-negative bacteria, although
a variety
of microorganisms have "endotoxin-like" components. Endotoxin is associated
with a
variety of negative effects on cells and tissues, including promoting cell
death and triggering
proinflammatory cytokines and nitric oxide. At sufficient levels in the body,
endotoxin can
produce "toxic shock," a life-threatening condition. Nakagawa et al.
(Nakagawa, Y. et al.
"Endotoxin Contamination in Wound Dressings Made of Natural Biomaterials, J.
Biomed.
Mater. Res. Part B: Appl. Biomater. 66B: 347-355, 2003) demonstrated that
endotoxin
contamination in nine different natural wound dressings could produce fever in
rabbits.
[004] A variety of methods have been developed for removing endotoxin from
proteins. These methods, however, do not lend themselves to the production of
large
quantities of endotoxin-free compositions. For years, complete endotoxin
removal was
usually achieved only with massive loss of substrate protein during the
process. More
recently, products have been developed for increased endotoxin removal with
significant
recovery of the substrate protein, but to date these products and the methods
upon which they
1
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
are based have not been suitable for the production of large quantities of
endotoxin-free
protein in a cost-effective manner. Some methods, such as that described by
Naidu (U.S.
Patent No. 7,125,963) utilize a multi-step, multi-reagent approach to
endotoxin removal. For
some products, it is desirable to limit the use of some of these reagents,
such as
detergents/surfactants, which can be costly when used in large quantities.
Thus such a
method may be cost-prohibitive for preparation of some products.
[005] Lactoferrin is a multi-functional protein belonging to the transferrin
family of
proteins. It is an 80 kDa protein, found primarily in milk and mucosal
secretions.
Lactoferrin binds iron, heparin, proteoglycan, DNA, oligodeoxynucleotides, and
LPS
(endotoxin). Two LPS binding sites have been identified in lactoferrin, the 28-
34 loop region
and an N-terminal four arginines (residues 2-5). The effectiveness of
lactoferrin against the
biological effects of endotoxins has been demonstrated. However, lactoferrin
readily binds
endotoxin¨and it would be desirable to remove the bound endotoxin and improve
the overall
benefit that lactoferrin can provide. Furthermore, it would be beneficial to
develop methods
for removing endotoxin from large quantities of a variety of different
proteins, and especially
from those proteins that bind endotoxin.
Summary of the Invention
[006] The invention relates to a method for removing endotoxin from a protein
composition and to products made (purified) by the method. In certain aspects,
the invention
relates to a method for removing endotoxin from protein, the method comprising
binding the
protein to a cationic exchange resin, eluting the endotoxin from the bound
protein using a low
ionic strength (i.e., low salt) solution without added surfactant, and eluting
the protein from
the resin using a high ionic strength solution such as high salt, acid, or
other suitable
compositions. In certain aspects, the method may further comprise the steps of
filtering the
eluted protein and drying the product of the ultrafiltration step. The method
may also
2
CA 02696145 2015-12-23
comprise using fractal distribution to apply the protein with bound endotoxin,
the low ionic strength
solution, and the high ionic strength solution to a cation exchange column.
[007] In one aspect, the invention relates to a method for removing endotoxin
from
lactoferrin, lactoferricin, lactoperoxidase, and/or other endotoxin-binding
proteins, as well as to
endotoxin-free products, such as endotoxin-free lactoferrin (EFL), produced by
the method. When
isolated from milk or a milk fraction, such a product may also comprise
additional milk-derived
factors having desirable properties, such as, for example, glycomacropeptide,
growth factors, or
other proteins, lipids, etc., and particularly those bovine milk-derived
agents having endotoxin-
binding or endotoxin-neutralizing activity. Compositions of the invention may
also comprise EFL
and xylitol, optionally supplemented with an antimicrobial composition
comprising silver.
[008] The invention also relates to methods for treating an acute wound and
for treating
biofilm-associated disease conditions, including chronic wounds, comprising
administering a
composition comprising a therapeutically-effective amount of an endotoxin-free
bovine milk-
derived lactoferrin.
[009] Methods may also comprise administering additional active agents such
as, for
example, activated lactoferrin, xylitol, an antimicrobial silver composition,
or a combination thereof.
[009a] The invention provides a method for producing a lactoferrin product
that is
substantially endotoxin-free, the method comprising a) binding a lactoferrin
in a liquid lactoferrin
composition to a cation exchange resin; b) washing the resin with water; c)
eluting the endotoxin
using a 0.01 to 0.5 molar salt solution, in the absence of added surfactant;
and d) eluting the
lactoferrin with an 80-100 mS/cm salt solution, to produce an eluted
lactoferrin product that is
substantially endotoxin-free.
3
CA 02696145 2015-12-23
Brief Description of the Drawings
[0101 Fig. 1 is a flow chart describing one embodiment of the present method
for removing
endotoxin from a protein composition.
[0111 Fig. 2 is a bar graph illustrating the results of an XTT assay performed
after 24-hour
exposure to the lactoferrin products indicated on the x-axis (media + serum +
product).
[012] Fig. 3 is a photograph of cells exposed to 1% low-endotoxin lactoferrin
(left) and to
1% medium-endotoxin lactoferrin (right). Media contained fetal calf serum.
3a
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
[013] Fig. 4 is a photograph of cells exposed to 2% low-endotoxin lactoferrin
(left)
and to 2% medium-endotoxin lactoferrin (right). Media contained fetal calf
serum.
[014] Fig. 5 is a photograph of cells exposed to 3% low-endotoxin lactoferrin
(left)
and to 3% medium-endotoxin lactoferrin (right). Media contained calf serum.
[015] Fig. 6 is a photograph of cells treated as control (EpiLife + 1% fetal
calf
serum, no lactoferrin added).
Detailed Description
[016] The inventors have developed a novel method for removing endotoxin from
a
protein. The method does not require the use of detergents/surfactants and,
unlike currently
available methods, is suited for producing kilogram quantities of endotoxin-
free protein in a
cost-effective manner. The method of the invention may be readily used to
produce large
(e.g., kilogram) quantities of bovine lactoferrin from milk or milk fractions,
for example.
The inventors have used the method to remove endotoxin from lactoferrin, and
thereby
produced an endotoxin-free lactoferrin (EFL) product. As used herein, the term
"endotoxin-
free" is intended to describe lactoferrin compositions comprising less than
about 20
endotoxin units per milligram of protein (EU/mg), more preferably less than
about 10
EU/mg, and even more preferably less than about 1 EU/mg, so the composition,
as compared
to lactoferrin isolates in the current commercial market, is substantially
endotoxin-free.
Included in the products made by the process of the invention are products
made from sweet
whey having from about 0 to about 20 EU/mg, products having from about 0 to
about 15
EU/mg, products having from about 0 to about 10 EU/mg, products having from
about 0 to
about 5 EU/mg, and products having less than 1 EU/mg, for example. Currently
available
commercial products, for example, may have at least about 20 EU/mg lactoferrin
if derived
from milk and at least about 250 EU/mg lactoferrin if derived from sweet whey.
For EFL
products derived from milk, "endotoxin-free" is intended to comprise EFL
products having
less than or equal to 1 EU/mg.
4
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
[017] Commercial products comprising lactoferrin isolated from milk and milk
fractions are produced by a number of companies. Tests of those products,
however,
demonstrate that such lactoferrin products contain amounts of endotoxin
associated with the
lactoferrin that are significant when viewed in the context of treatment of
wounds,
particularly (see Table 1). The method of the present invention provides a
means by which
large quantities of EFL may be produced from bovine milk and/or one or more
milk fractions,
for example, yielding a product that has significantly lower endotoxin levels
and has been
demonstrated to provide a more beneficial effect to cells that inhabit the
wound environment
than do bovine milk-derived lactoferrin products presently available in the
market.
Table 1
Levels of Lactoferrin-Associated Endotoxin in Commercial Milk-Derived
Lactoferrin
Isolates
Product Number Lactoferrin Endotoxin Level
Source
(expressed as endotoxin units
per milligram)
1 Sweet whey 1000-1250 EU/mg
2 Sweet whey 250-300
3 Sweey whey 250-300
4 Milk 20
[018] Previously described methods for removing endotoxin from proteins such
as
lactoferrin, for example, relied on the use of surfactants to aid in
separation of the bound
endotoxin from the lactoferrin. Surfactants, however, are expensive and the
use of
surfactants to remove endotoxin from protein is cost-prohibitive when larger-
scale processes
are required in order to make commercial quantities of endotoxin-free protein.
The inventors
have discovered that the use of a combination of low-ionic strength (e.g, low
salt) solution
used to elute endotoxin from a protein that is tightly bound to a cation
exchange column,
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
followed by elution of the protein with a high ionic strength (e.g., high
salt, acid, etc.)
solution, eliminates the need for the surfactant. Low salt solutions may
comprise, for
example, 0.01 to 0.5 molar salt solutions and in some embodiments may
comprise, for
example, 0.25 to 0.35 molar salt solutions. Methods for making such solutions
and for
selecting the appropriate ionic strength, molarity, etc. for ion exchange
methods, are known
to those of skill in the art.
[019] Lactoferrin binds a number of compounds, including iron, heparin,
proteoglycan, DNA, oligodeoxynucleotides, and LPS (endotoxin). Two LPS binding
sites
have been identified in lactoferrin, the 28-34 loop region and an N-terminal
four arginines
(residues 2-5). The effectiveness of lactoferrin against the biological
effects of endotoxins
has been demonstrated. Lactoferrin is especially effective for the inhibition
of biofilm
reconstitution in a chronic wound, and compositions of the present invention
may be used in
methods for inhibiting both biofilm formation and reconstitution. Such
compositions may
also provide effective treatment for acute wounds in which biofilm has not yet
developed,
since the endotoxin provided by a lactoferrin composition other than an EFL is
detrimental to
primary human keratinocytes and is known to produce a triggering effect on the
inflammatory response, which may actually delay wound healing. Non-EFL
compositions
may therefore not provide as rapid a wound-healing response as do EFL
compositions.
[020] The method for removing endotoxin from a protein comprises the steps of
passing a liquid composition comprising the protein with bound endotoxin
through a cation
exchange system to bind a protein to the cation exchange resin, eluting the
endotoxin from
the protein using a low-ionic strength solution such as, for example, a low
salt solution,
eluting the protein from the cationic exchange resin using a high-ionic
strength solution such
as, for example, a high salt solution, one or more acids, etc., optionally
followed by the steps
of filtering the eluted protein and drying the protein. Drying the protein may
be
accomplished using methods know to those of skill in the art, such as freeze-
drying, spray-
6
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
drying, etc. Filtration may be performed, for example, using ultrafiltration
methods known to
those of skill in the art. In some embodiments, the step of binding the
protein to the cation
exchange resin may be performed using a cation exchange column such as those
manufactured and/or made commercially available by BioRad, Amalgamated
Research, Inc.,
and others. The inventors recommend that the cation exchange resin be selected
to tightly
bind the protein to be purified in order to maximize the efficiency of the
process.
[021] The method may be performed according to the following example. Process
conditions are suggested, but are not intended to be limiting, as it is well
within the skill of
those in the art to modify these process conditions, depending upon the cation
exchange
system used, the ultra-filtration system/method used, etc. The inventors
suggest that all
processes be performed at or below 40 degrees Fahreinheit in order to limit
potential
microbial contaminant growth. This process may also be illustrated by the flow
chart in Fig.
1. Briefly, an ion exchange column, such as a 300 mm x 200 mm ARi custom ion
exchange
column (Amalgamated Research, Inc.) with fractal distribution heads and having
a column
volume of approximately 9.5 L, is prepared for loading by the addition of at
least 3 or more
column volumes of caustic agent (0.2N) at a flow rate of 400-500 liters per
hour, followed by
down flow or no flow prior to the addition of buffer (e.g., phosphate buffer,
1% at pH 6-7.5)
with a flow rate of 50-400 liters per hour to flush until the pH reaches less
than about 8. Salt
is then added as a 1 molar 80-100 mS/cm solution and the flow rate is adjusted
to about 50-
400 liters per hour for one or more column volumes (preferably 2) and the
column is flushed
with water at a flow rate of 50-500 liters per hour. For all the above steps,
a flow rate of 300
liters per hour for a column such as the ARi 300 mm x 200 mm is recommended.
As is
known to those of skill in the art, various column sizes may be used and
volumes adjusted
accordingly.
[022] The column is then loaded with a liquid lactoferrin composition (5 ¨
10%),
one example of such a composition being commercially available and sold as
Bioferrin 2000
7
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
(Glanbia Nutritionals, Inc., Monroe, Wisconsin). The liquid lactoferrin
composition may be
derived or obtained from a variety of sources, including sweet whey, milk,
and/or milk
fractions, for example, and may include various forms of lactoferrin such as
metal-saturated
(holo) lactoferrin and metal-free (apo) lactoferrin. Other proteins and milk-
derived
substances may also be included in a liquid lactoferrin composition, but such
a composition
will preferably be an enriched lactoferrin composition or a purified
lactoferrin composition.
For the column described above, 1.5 to 20 liters of liquid lactoferrin
composition is loaded
onto the column, with 10 liters being recommended. Flow rate is adjusted to 50
to 400 liters
per hour (100 liters per hour recommended), down flow. The column is then
flushed with
one or more column volumes of water at a flow rate of 50-400 liters per hour.
Without being
bound by theory, the inventors believe that fractal distribution provides an
added benefit for
the removal of endotoxin via ion exchange, such as in the cation exchange
method described
herein.
[023] Next, a low salt solution (28-37 mS/cm) is added to the column and flow
is
adjusted to 50-400 liters per hour (150 liters per hour recommended) so that
the low salt
solution is run through the column at 2 or more column volumes. A high salt
solution (80-
100 mS/cm) is then added at one or more column volumes (1.4 recommended), and
flow is
adjusted to 50-400 liters per hour (200 liters per hour recommended). The
column is then
flushed with water at one or more column volumes and a flow rate of 50-400
liters per hour
(360 liters/hour recommended), followed by a citric (0.5% citrate) flush
upflow for 1 or more
column volumes at a flow rate of 50 to 400 liters/hour (300 L/hr preferred).
The citrate flush
upflow is followed by a citrate flush downflow of 3 or more column volumes at
a flow rate of
50-400 liters/hour (preferably 300 liters/hour).
[024] A water flush is then performed using at least two column volumes of
water at
a flow rate of 50-400 liters/hour (400 L/hr), followed by the addition of a
high salt solution
(80-100 mS/cm) for 1 or more column volumes at a volume of 50-400 liters/hour
(300 L/hr).
8
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
At least two column volumes of water is then run through the column. Endotoxin-
free
protein (lactoferrin) is collected in suitable containers such as sterilized
buckets, stainless
steel tanks, etc.
[025] Product from the ion exchange system is then subjected to ultra-
filtration.
Briefly, the endotoxin-reduced product from the ion exchange system is
transferred into a
refrigerated balance tank until full, or until the desired batch quantity is
achieved. The ultra-
filtration system (10kDa membrane) is operated at 40 F or less. Product is
concentrated to
about 4% solids and diafiltration water is then added until the conductivity
of the retentate is
less than 8.0 mS/cm. Liquid is drained into an endotoxin-free container and
kept at a
temperature of less than about 40 F. The ultrafiltration device is cleaned
using Ecolab AC-
55-5 acid cleaner (500 m1/25 gal), which is circulated for at least 30 minutes
to 1 hour.
Caustic is used to clean by circulating 0.2M for at least 6 hours, and
preferably for 12 hours.
Next, the system is rinsed with endotoxin-free water (0.2 EU/ml) until the pH
is less than 8Ø
(Water filtration is performed using a Flow Solutions AB3NFZ7PH4 system.)
[026] For freeze-dried product, all product contact surfaces should be soaked
with
0.2M caustic for at least 6 hours, and preferably 12 hours or more, followed
by thorough
rinsing with endotoxin-free water prior to making contact with the product. A
suitable
method for drying the product may be chosen from among methods known to those
of skill in
the art, including, for example, freeze-drying, spray-drying, and other
methods. The resulting
powder may be packaged into one or more suitable endotoxin-free containers.
[027] Methods for purification and isolation of LF from a variety of sources
have
been described, for example, in U.S. Pat. Nos. 4,190,576; 4,436,658;
4,667,018; 4,668,771;
4,791,193; 4,997,914; 5,087,369; 5,149,647; 5,169,936; 5,179,197; 5,516,675;
5,571,896;
5,596,082; 5,756,680; 5,849,885; 5,861,491; 5,919,913; 6,010,698; 6,096,870
and 6,268,487.
Liquid lactoferrin compositions for use in the method may comprise any
lactoferrin-
containing composition, but preferably comprise an enriched concentration
(i.e., greater than
9
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
2%) of lactoferrin. Lactoferrin may be isolated directly from milk, or may be
isolated from
milk fractions such as whey and/or whey protein isolate, for example. In
industry terms, such
a lactoferrin product would be considered to be "enriched" or "substantially
purified." Such
a composition may also include other compounds found in milk or milk isolates,
including
lactoperoxidase, growth factors, calcium, and other compositions.
[028] In one aspect, a milk-derived lactoferrin product (MDLF) comprises at
least
about 10% bovine lactoferrin, which may have an iron content of from about
15mg/100g to
about 40mg/100g. In other aspects, the MDLF may comprise at least about 50%,
at least
about 75%, or at least about 90% lactoferrin. Some forms of MDLF may also
comprise the
apolactoferrin form of lactoferrin, providing an iron concentration of from
about Omg/100g to
about 15mg/100g. In some embodiments, apolactoferrin may comprise an iron
concentration
of from about 4 mg/100g to about 15 mg/100g.
[029] Bioferrin 1000 (Glanbia Nutritionals, Inc.) is a natural, biologically-
active
milk-derived protein product comprising bovine apolactoferrin from fresh sweet
whey. It is
isolated using fractionation separation techniques known to those of skill in
the art and
comprises greater than 90 percent protein, with greater than 90% of the total
protein (e.g.,
95%) comprising lactoferrin, primarily in the apolactoferrin form (<15 mg
iron/100 g).
Bioferrin 2000 is a similar product, except that iron is present at a level
that is from about
15 to 40 mg/100 grams of product.
[030] A composition comprising bovine lactoferrin in the apolactoferrin form
and/or
the higher-iron form may be used in the method of the present invention to
produce an
endotoxin-free product. Generally, for wound care, the apolactoferrin form may
provide
additional benefits, although both forms have been demonstrated to be
effective. Endotoxins
are lipopolysaccharide products released when Gram-negative bacteria such as
Escherichia
coli and Pseudomonas aeruginosa die. Wounds that are difficult to treat with
standard
wound-care methods generally contain established biofilm, which is more often
than not
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
comprised of a mixed population of microorganisms. Endotoxin production within
a biofilm
has been reported to be at least approximately 1000 units/cm2 (Rioufol, C. et
al. J. Hosp
Infect. (1999) 43: 203-209). Studies done at the Center for Biofilm
Engineering at Montana
State University have demonstrated that a log reduction in biofilm associated
with
hemodialysis tubing is correlated with a linear reduction in endotoxin level.
Additional
studies done at Montana State's CBE have also demonstrated that a biofilm
comprising
primarily Pseudomonas aeruginosa produces approximately 3,100 to 6,200 (mean
4,300)
endotoxin units per square centimeter of biofilm. Chronic wounds are
characterized by
increased pro-inflammatory cytokines, increased matrix metalloproteases, low
levels of tissue
inhibitors of matrix metalloproteases, and low levels of growth factor
cytokines, as well as
degraded receptors on the cells constituting the wound bed (senescent cells).
Many of these
characteristics have been associated with endotoxin. In the wound environment,
endotoxins
have been found to stimulate the production of inflammatory mediators such as
TNF-a and
interleukins, which stimulate production of matrix metalloproteinases (MMPs).
Non-healing
wounds have been associated with prolonged increased levels of MMPs, which may
contribute to the degradation of growth factors, cellular receptors, and other
components of
healthy tissue. Bacterial endotoxins decrease wound tensile strength, decrease
collagen
deposition and cross-linking, and have been associated with surgical wound
dehiscence
(Metzger, Z. et al. (2002) J. Endod. 28(1): 30-33.) For an acute wound,
especially, an EFL
product of the invention may be particularly beneficial, as such a product
will limit the
potential for cell death and an undesirable immune response in the wound
tissue that may
slow the wound-healing process.
[031] The invention also provides an endotoxin-free lactoferrin (EFL) made by
the
aforementioned method. Lactoferrin protein compositions from human or animal
origin,
made via recombinant DNA technology methods or isolated from milk may be
purified by
the method of the present invention. EFL may be especially effective for
applications where
11
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
lactoferrin is suggested to provide a benefit, but where the effects of
lactoferrin-bound
endotoxin are especially undesirable. EFL of the present invention may be
incorporated into
mouthwash, toothpaste, nutritional drinks, foods, wound care products such as
creams, gels,
bandages and other wound care products, cosmetic products such as creams,
lotions, and gels
used for a variety of applications, including anti-aging, acne medication, and
other uses. EFL
may be used for the treatment of acute and/or chronic wounds. EFL may be
provided for all
the above-mentioned uses, and for other uses, in combination with other active
agents, such
as xylitol, antibiotics, antioxidants, and other agents chosen for the
particular purpose for
which the EFL composition is to be formulated, such as for wound care, oral
care, and/or skin
care.
[032] A composition comprising bovine milk-derived and/or whey-derived
lactoferrin has recently been shown to provide a safe, highly-effective,
plentiful and
affordable topical wound care agent. Compositions of the present invention
have been shown
by the inventors to be superior to current commercially-available bovine
lactoferrin
compositions in terms of promoting cell viability of primary human
keratinocytes, a cell type
known to be necessary for wound healing. As illustrated by figures 2 through
8, when "low-
endotoxin" (i.e., approximately 400 EU/mg) and "medium-endotoxin" (i.e.,
approximately
0.40 EU/mg) compositions are compared in keratinocyte cell cultures with or
without serum
added to the media, the addition of the medium-endotoxin product produces
significant cell
death in both the presence and absence of serum, while cell viability is
maintained in the
cultures to which the low-endotoxin product is added. For acute wound care,
this difference
may be especially beneficial. A significant difference between acute and
chronic wounds is
that chronic wounds are generally associated with the presence of bacterial
biofilm.
Endotoxins from the bacteria produce a cascade of cellular and immunological
effects that is
generally considered to delay the wound-healing process. While lactoferrin
promotes wound
healing, human lactoferrin must generally be derived via recombinant DNA
methods which
12
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
may be expensive and may also yield a protein with associated endotoxin, and
bovine
lactoferrin, while providing a more readily available source of endotoxin, is
also likely to be
associated with bound endotoxin. Bovine lactoferrin purified by the method of
the invention
provides a wound care composition that may be especially effective for
application to acute
wounds via powders, gels, creams, ointments, bandages, or other
compositions/products, as
this form of lactoferrin does not introduce endotoxin into the wound
environment and, as
demonstrated by the experiments described herein, does not contribute to
keratinocyte death.
[033] Based on the results of the inventors' comparison between EFL and higher-
endotoxin products, they also provide here a method for improving healing in
chronic and
acute wounds, as well as a method for reducing biofilm formation and
reconstitution in
conditions that are associated with biofilm formation and reconstitution,
which include, but
are not limited to, contact-lens-associated keratitis, endophthalmitis, otitis
media, chronic
tonsillitis, chronic rhinosinusitis, burn wounds, decubitus ulcers, surgical
site infections,
diabetic foot ulcers, inflammatory bowel disease, peptic ulcers, surface
wounds associated
with post-operative infection, and vaginosis. A variety of uses for human are
described, for
example, in U.S. Patent Number 6,455,687. ELF of the present invention is also
suited for
use for therapeutic uses which have been identified for human lactoferrin. For
these and
other conditions associated with biofilm establishment and reconstitution,
compositions
comprising EFL may be provided and administered as eye drops, ear drops, oral
sprays,
lozenges, quick-dissolve strips, nasal sprays, sinus irrigation solutions,
ointments, creams,
gels, components of bandages, tablets, caplets, capsules, liquids, and other
use-appropriate
compositions that may additionally comprise appropriate excipients,
flavorings, colorings,
and additional active agents.
[034] Endotoxin-free lactoferrin compositions are especially suited for
application to
tissues that may be especially endotoxin sensitive, and endotoxin-free
lactoferrin
compositions of the present invention that are made by the method of the
invention may be
13
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
applied to devices that may be implanted into tissues, such as orthopedic
implants, ocular
prostheses, contact lenses, and intrauterine contraceptive devices.
[035] Lactoferrin has also been demonstrated to be beneficial as a
prophylactic agent
against viral infection. For that purpose, it may be provided for oral
administration via a
variety of vehicles for administration of therapeutic agents, such as, for
example, tablets,
effervescent tablets, oral strips such as those made of pullulan that may be
placed on the
tongue, etc., or may be provided, for example, via nasal and/or throat sprays.
EFL
compositions of the present invention may be especially beneficial for use as
nasal sprays. In
rats, an animal model for immune response to endotoxin, inhaled endotoxin
produces a dose-
dependent response in rat nasal and tracheobronchial airways (Gordon, T. and
J.R. Harkema,
Am. J. Respir. Cell Mol. Biol., Vol. 10, No. 2, p. 177-183 (1994)). EFL
compositions of the
present invention may therefore provide lactoferrin for use in nasal sprays
for prophylactic
use against respiratory virus infection, while avoiding the mucous secretions
and associated
discomfort that may be associated with nasal endotoxin exposure.
[036] In various embodiments, compositions comprising EFL may also comprise at
least one additional agent for topical application to a wound, such as, for
example, a
moisturizing agent, a hydrocolloid gel, a saline composition, a medium-chain
dextran (e.g.,
honey), etc., for application to an acute or chronic wound. Commercially
available
compositions such as, for example, DuoDerme Hydroactive Dressings (Bristol-
Myers
Squibb, Princeton, NJ), can be used as a base into which a suitable amount of
EFL
(Bioferrin , Glanbia Nutritionals, Inc., Monroe, WI) is admixed. Moisturizing
agents
suitable for wound care are known to those of skill in the art, and a number
of such agents are
commercially available.
[037] A wound healing composition, and a method of healing wounds by
administering the composition, may comprise EFL and xylitol. Such a
composition may also
optionally comprise antimicrobial agents such as antibiotics, moisturizers, or
other agents to
14
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
improve the rate of wound healing, as well as excipients and compositions for
facilitating
topical application of the EFL/xylitol.
[038] Compositions of the present invention may readily be used in conjunction
with
compositions and devices containing antimicrobial preparations of silver.
Compositions may
comprise, for example, EFL or EFL-A, xylitol, and a silver product such as
Acticoat (Smith
and Nephew, Memphis, Tennessee). Acticoat , for example, may provide
antimicrobial
silver as a rayon/polyester non-woven core laminated between an upper and
lower layer of
silver-coated high density polyethylene (HDPE) mesh. Acticoat Moisture
Control (Smith
and Nephew, Memphis, Tennessee) is a foam dressing comprising silver in
nanocrystalline
form. Actisorb Silver products distributed by Johnson and Johnson comprise
activated
charcoal cloth impregnated with silver (33 p,g silver per square cm of cloth).
Arglaes
products (Giltech Ltd., UK) also provide polymers for release of silver ions
from a powder,
film dressing, or other preparation for application to a wound. Compositions
of the present
invention may be incorporated into such products or used in combination with
such products.
One advantage of augmenting the use of silver products with the use of
compositions
described by the invention is the ability to incorporate less silver into the
products while
achieving an improved effect on wound healing. As used herein in regard to
silver-
containing wound dressings, both compositions and devices are included, and
may include
woven or non-woven fabrics or polymers, alginates, foams, powders, gels,
creams, liquids,
wound fillers and other pharmaceuticals or medical devices deemed by those of
skill in the
art to be appropriate for effective delivery of silver compositions to a
wound.
[039) Activated lactoferrin and methods for producing activated lactoferrin
have
been described by Naidu in United States Patent Number 6,172,040. Naidu
describes the
immobilization of lactoferrin on a substrate to which lactoferrin readily
binds in order to
increase its iron-binding capacity. A composition comprising an activated form
of lactoferrin
in combination with an EFL may also provide an effective wound care
composition.
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
[040] For acute wound care, EFL compositions of the invention made by the
method
of the invention may be also applied to a bandage to increase wound healing.
[041] Compositions of the invention may be administered to humans and/or
animals
and methods for use of such compositions are also suitable for humans and/or
animals.
[042] The invention may be further described by means of the following non-
limiting examples.
Examples
Example 1- Preparation of EFL
[043] Ion exchange was performed as described above. Tables 2 and 3 illustrate
the
results obtained by the method described herein.
Table 2. Individual Ion Exchange Lots
LAL LAL LAL
(EU/mg) (EU/mg) (EU/mg)
(Limulus (Limulus (Limulus
Amibocyte Amibocyte Amibocyte
Lysate Lysate Lysate
Plate Plate Plate
(Kinetic (Kinetic (Kinetic
Technique) Technique) Technique)
Day/Run Method) Day/Run Method) Day/Run Method)
1/1 0.701 9/1 0.331 13/5 0.233
1/2 0.739 9/2 0.199 13/6 0.15
2/1 2.8 9/3 0.411 14/1 0.299
2/2 7.356 9/4 0.428 14/2 0.162
2/3 6.88 9/5 0.255 14/3 0.148
3/1 4 9/6 0.121 15/1 0.2398
3/2 2.15 10/1 0.23 15/2 0.137
4/2 0.07 10/2 0.12 15/3 0.323
5/3 1.88 10/3 0.131 15/4 0.159
5/4 1.95 10/4 0.47 15/5 0.0788
5/5 1.02 10/5 0.258 15/6 0.091
6/1 0.33 11/1 1.14 15/7 0.137
6/2 0.39 11/2 4.87 16/1 1.676
6/3 0.81 11/3 7.413 16/2 0.731
6/4 0.61 11/4 2.373 16/3 0.803
6/5 1.54 12/1 0.349 16/4 0.724
7/6 2.45 13/1 0.327 16/5 1.015
8/1 , 0.32 13/2 0.19 17/1 0.158
8/2 0.958 13/3 0.205 17/2 0.419
8/3 1.353 13/4 0.125
16
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
Table 3. Daily Average Results of Limulus Amoebocyte Asssay
Average or
Batches Comped
Day Produced EU
1 2 0.117
2 6 0.275
3 5 0.242
4 4 1.315
1 0.349
6 6 0.168
7 5 0.185
8 7 0.179
9 5 1.015
8 0.291
11 9 0.465
Example 2 ¨ Product Comparison in Keratinocyte Scratch Assay, No Serum in
Media
[044] Primary human keratinocytes were seeded in 24-well plates and grown to
90-
95% confluence. A scratch was made down the center of the well, using a 200
microliter
pipet tip. Plates were washed with HEPES-buffered saline and imaged (T=0).
Three hundred
microliters of product (standard commercially-available bovine lactoferrin
product = medium
endotoxin, product produced by the method of the invention = low endotoxin)
were added to
the corresponding wells and cells were incubated at 37 C at 5% CO2. At 24-hour
intervals,
media and product were removed by aspiration, cells were washed with buffered
saline, and
fresh media with product were replaced. Cells were returned to the incubator
after washing
and media/product change. The assay was terminated after 72 hours. Product
tested
comprised 1% of the low endotoxin product (EFL) in cell culture medium, 2% of
the low
endotoxin product (EFL) in cell culture medium, 1% of the high endotoxin
product
(commercially available product, isolated lactoferrin, no endotoxin removal
method used) in
cell culture medium, and control (cell culture medium only). Cell culture
medium did not
contain fetal bovine serum/fetal calf serum.
17
CA 02696145 2010-02-10
WO 2009/009706 PCT/US2008/069713
[045] When the cells were observed for closure of the scratch area, it was
noted that
although neither of the scratch areas had yet closed, a more notable effect
was that the cells
treated with high-endotoxin lactoferrin were dead or dying at a rapid rate,
although the
endotoxin was bound to lactoferrin and presumably neutralized by it.
[046] An XTT assay was performed as follows: after 72 hours, product and media
were removed from the plates, cells were washed with HBS, and 300 microliters
of each cell
culture medium plus 60 microliters XTT were added to each well. As a control,
two wells
with medium plus XTT, but without cells, were used. The XTT assay measures
cleavage of
the tetrazolium ring of XTT due to mitochondrial dehydrogenase activity,
expected to be
higher in viable cells, yielding orange formazan crystals and turning the
medium from pink to
orange. After 4 hours, medium was sampled and absorbance at 490 nm was
measured for
each sample. Cell viability was then assayed via Trypan Blue Exclusion.
Example 3 - Product Comparison in Cultured Primary Human Keratinocytes, Serum
Added
[047] Primary human keratinocytes were seeded in 24-well plates and grown to
70%
confluence. Plates were washed with HEPES-buffered saline and imaged (T=0).
Three
hundred microliters of product (standard commercially-available bovine
lactoferrin product =
medium endotoxin, product produced by the method of the invention = low
endotoxin) were
added to the corresponding wells and cells were incubated at 37 C at 5% CO2.
Samples
tested were 1% low- endotoxin lactoferrin + culture medium, 2% low-endotoxin
lactoferrin +
culture medium, 3% low-endotoxin lactoferrin + culture medium, 1% medium-
endotoxin
lactoferrin + culture medium, 2% medium-endotoxin lactoferrin + culture
medium, 3%
medium-endotoxin lactoferrin + culture medium, and control (cell culture
medium only). At
24 hours, media/product was removed, cells were washed, and 300 microliters of
fresh
medium plus 60 microliters of XTT were added. Cells were incubated for an
additional 4
18
CA 02696145 2010-02-10
WO 2009/009706
PCT/US2008/069713
hours, then samples were taken and absorbance was measured at 490 nm. Readings
were
blanked to controls (cell culture medium + XTT). Results are shown in figure
2.
[0481 As shown in figures 3-6, application of low-endotoxin product to cells
significantly increases cell viability over that seen after application of
medium-endotoxin
product.
19
